Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

NCT06235775 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: GV1001 Placebo
DRUG: GV1001 1.12mg

Sponsor

GemVax & Kael